Dichlorophenylacrylonitriles as AhR Ligands displaying selective breast cancer cytotoxicity in vitro

    Jennifer R Baker1, Jayne Gilbert2, Stefan Paula3, Xiao Zhu3, Jennette A Sakoff2, Adam McCluskey1

    • 1 The University of Newcastle, Chemistry, Newcastle, Australia
    • 2 Calvary Mater Hospital, Medical Oncology, Newcastle, Australia
    • 3 Purdue University, Chemistry, West Lafayette, United States

    Knoevenagel condensation of 3,4‐dichloro‐ and 2,6‐dichloro‐ phenylacetonitriles gave a library of dichlorophenylacrylonitriles. Our leads 5 and 6 displayed 0.56±0.03 and 0.127±0.04 μM growth inhibition (GI₅₀) and 260‐fold selectivity for the MCF‐7 breast cancer cell line. A 2,6‐dichlorophenyl moiety saw a 10‐fold potency loss; additional nitrogen moieties (‐NO₂) enhanced activity (26 and 27), with the corresponding ‐NH₂ analogues (29 and 30) more potent. Despite this, both 29 (2.8±0.03 μM) and 30 (2.8±0.03 μM) were 10‐fold less cytotoxic than 6. A bromine moiety effected a 3‐fold enhancement in solubility with 18 relative to 5 at 211 μg mL‐1. Modelling led synthesis saw the introduction of 4‐aminophenyl substituent gave 35 and 38, 0.030±0.014 and 0.034±0.01 μM potent, respectively. Other analogues, e.g. 35 and 36, were sub‐micromolar potent against our cell line panel (HT29, colon; U87 and SJ‐G2, glioblastoma; A2780, ovarian; H460, lung; A431, skin; Du145, prostate; BE2‐C neuroblastoma; MIA, pancreas and SMA murine glioblastoma) except 35 against U87. A more extensive evaluation of 38 ((Z)‐N‐(4‐(2‐cyano‐2‐(3,4‐dichlorophenyl)vinyl)phenyl)acetamide), in a panel of drug resistant breast carcinoma cell lines showed 10‐206 nM potency against MDAMB468, T47D, ZR‐75‐1, SKBR3 and BT474. MOE docking scores showed a good correlation between predicted binding efficiencies and observed MCF‐7 cytotoxicity. This supports the use of this model in developing breast cancer specific drugs.

    Read the publication that featured this abstract

    Get in touch

    For more information on flow chemistry systems and services please use the contact methods below.

    Call us on +44 (0)1284 728659 or Email us